Please enter your username and password below, if you are not yet a member of BioTechniques remember you can register for ...

Tech oligarchs’ wildest visions of tomorrow amount to a modern secular theology that is both mesmerizing and, in his view, ...

We’ve entered an era where biometric identity is currency. Regeneron just cornered a market without asking the public, the ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

In my past stints at Forbes India, the Economic Times, Business Standard and Businessworld, I have written on technology, finance, management, and strategy over a career spanning three decades. My ...